CINGULATE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.701 USD | -2.26% |
|
-11.12% | -90.84% |
| May. 21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
| May. 08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.56M |
|---|---|---|---|---|---|
| Net income 2024 * | -10M | Net income 2025 * | -13M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.34
x | P/E ratio 2025 * |
-0.3
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.26% | ||
| 1 week | -11.12% | ||
| 1 month | -32.60% | ||
| 3 months | -47.69% | ||
| 6 months | -88.55% | ||
| Current year | -90.84% |
1 week
0.65
0.80
1 month
0.651.15
Current year
0.658.90
1 year
0.6521.20
3 years
0.65103.00
5 years
0.65103.00
10 years
0.65103.00
| Managers | Title | Age | Since |
|---|---|---|---|
Matthew Brams
FOU | Founder | 61 | 12-12-31 |
Raul Silva
FOU | Founder | 67 | 12-12-31 |
Shane Schaffer
CEO | Chief Executive Officer | 49 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Werth
BRD | Director/Board Member | 85 | 18-05-31 |
Jeffrey Ervin
BRD | Director/Board Member | 46 | Feb. 12 |
Shane Schaffer
CEO | Chief Executive Officer | 49 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.701 | -2.26% | 62,576 |
| 24-05-30 | 0.7172 | +2.46% | 102,091 |
| 24-05-29 | 0.7 | -1.09% | 135,623 |
| 24-05-28 | 0.7077 | -10.27% | 339,816 |
| 24-05-24 | 0.7887 | -4.40% | 158,811 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Companyâs CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Calendar
2024-06-11
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.701
USD
Average target price
14
USD
Spread / Average Target
+1,897.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -90.84% | 4.56M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- CING Stock
